Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Bevacizumab
100%
Stem Cells
100%
Xenograft Model
100%
Intra-arterial Delivery
100%
Intra-arterial
62%
Tumor-initiating Cells
37%
Tumor Tissue
25%
Blood-brain Barrier Disruption
25%
Cell-based
12%
Tumor
12%
Tumor Progression
12%
Tumor Growth
12%
Firefly Luciferase
12%
Treatment Modalities
12%
Immunohistochemistry
12%
Vascular Endothelial Growth Factor
12%
Treatment Effect
12%
Cortex
12%
Glioblastoma multiforme
12%
Saline Injection
12%
Nude Mice
12%
Xenograft Mouse Model
12%
Xenograft
12%
Animal Survival
12%
Bioluminescence Imaging
12%
Tumor Formation
12%
Infiltrative Growth Pattern
12%
Human Glioblastoma
12%
Humanized
12%
Patient Tumor
12%
Bevacizumab Treatment
12%
Intravenous Treatment
12%
Intra-arterial Chemotherapy
12%
Recurrent Glioblastoma multiforme
12%
Injection Control
12%
Medicine and Dentistry
Bevacizumab
100%
Glioblastoma
100%
Xenograft
100%
Cancer Stem Cell
44%
Neoplasm
22%
Tumor Progression
22%
Blood Brain Barrier
22%
Carcinogenesis
11%
Immunohistochemistry
11%
Western Blot
11%
Treatment Effect
11%
Intraarterial Drug Administration
11%
Vasculotropin
11%
Luciferase
11%
Blotting
11%
Table Salt
11%
Firefly Luciferase
11%
Bioluminescence
11%
Immunology and Microbiology
Xenograft
100%
Bevacizumab
100%
Cancer Stem Cell
44%
Blood Brain Barrier
22%
Western Blot
11%
Nude Mouse
11%
Mouse Model
11%
Vasculotropin
11%
Bioluminescence
11%
Neuroscience
Bevacizumab
100%
Cancer Stem Cell
44%
Blood Brain Barrier
22%
Glioblastoma Multiforme
22%
In Vivo
11%
Western Blot
11%
Carcinogenesis
11%
Vascular Endothelial Growth Factor
11%
Immunohistochemistry
11%
Luciferase
11%
Bioluminescence
11%